The software, which also received a CE mark in January, is employed during the time a first-line provider is reviewing a patient’s images, and is intended to highlight cases in need of a specialist consultation earlier than they normally would be. Viz.ai received de novo 510(k) clearance for Contact in February, just a few months after the agency released its long-awaited draft guidance on CDS products that outlined which tools would and would not be regulated by the agency. In contrast, physicians and their teams are driving adoption of the Viz.ai platform because it is not disruptive to emergency room procedures and fits naturally into existing systems.” “Many new health-tech solutions struggle to gain traction because they are an outside-in sale to medical teams, requiring changes to procedures and workflows. “We were attracted not only to the technology behind Viz.ai and its impact on patient outcomes, but also its adoption model,” Mamoon Hamid, a general partner at Kleiner Perkins who will be joining Viz.ai’s board, said in a statement. According to today’s statement, the company will be using its new backing to expand its offering into new markets, and to extend its product portfolio to conditions outside of stroke. Viz.ai’s primary product is Contact, the first FDA-cleared clinical decision support (CDS) tool that analyzes CT results and highlights cases that may have experienced a stroke for review by a neurovascular specialist.
The investment was led by Kleiner Perkins, with additional participation from GV (formerly Google Ventures). Healthcare AI company Viz.ai announced today that it has raised $21 million in Series A funding.
0 kommentar(er)
